Failed in phase 3
Lipid / vascular (statins etc.): slow disability worsening in secondary progressive MS
secondary progressive MS · Lipid / vascular (statins etc.)
Controlled phase 3 trials did not meet their main goal for this group. This does not rule out the mechanism in other groups or with other medicines.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 964
How the verdict was reached
Not supported in phase 3
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| MS-STAT2 | Phase 3 | 964 | 2018 | Missed its main goal 173 (36%) of 482 participants in the placebo group and 192 (40%) of 482 participants in the simvastatin group had 6-month confirmed disability progression (adjusted hazard ratio 1·13 [95% CI 0·91 to 1·39], p=0·26). Paper abstract | Counted |
Counted: 1. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026Status changed from Results pending to Failed in phase 3
- Oct 2026First listed as Results pending
Related hypotheses
Assembled by software from public sources.